Market taxonomy by Types distinguishes three methodological families that underpin the Cell‑Free Circulating Tumor DNA (ctDNA) market. PCR‑based platforms, principally digital droplet PCR (ddPCR) and BEAMing, represent the most cost‑effective solution for single‑mutation quantification, contributing approximately 40 % of assay revenue due to their low instrument cost and rapid turnaround. NGS‑based approaches, divided into targeted‑panel sequencing and whole‑genome sequencing (WGS), account for roughly 45 % of the market; targeted panels dominate because they balance breadth of coverage with manageable data‑analysis pipelines, while WGS, though still niche, commands premium pricing for comprehensive genomic profiling. Methylation‑focused assays, which interrogate epigenetic signatures rather than sequence variants, hold an emerging 15 % share, driven by their superior sensitivity in early‑stage disease and growing validation in clinical trials. The relative weight of each type is shaped by factors such as limit‑of‑detection requirements, reimbursement pathways, and the intended clinical decision point, thereby influencing overall market size and growth trajectory. Consequently, vendors prioritize hybrid workflows that combine PCR precision with NGS breadth to capture a larger share of forthcoming contracts.